Turmeric Effect on Reduction of Serum Prolactin and Related Hormonal Change and Adenoma Size in Prolactinoma Patients

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01344291

Enrollment

Registered

2011-04-29

Start date

2011-07-31

Completion date

2012-08-31

Last updated

2011-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperprolactinoma

Keywords

hyperprolactinoma, turmeric, amenorrhea

Brief summary

Prolactinoma is the most prevalent anterior hypophysis tumor. The principal treatment for this disorder is Dopamine agonist drugs including bromocriptin and Cabergoline. However, 50% of Bromocriptin treated and 17% of Cabergoline treated patients are resistant to these drugs. Curcumin is the main derivative of turmeric ,an old spice which is used frequently in Indian and Iranian cuisine. It has been proved that curcumin can reduce mammotrope cells proliferation and also intracellular hormone production. The purpose of this study is to evaluate the effect of turmeric on prolactinoma patients.

Interventions

DRUGCurcumin

Curcumin is prescribed to new cases of hyperprolactinoma

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 45 Years

Healthy volunteers

Inclusion criteria

* hyperprolactinemia * microprolactinoma

Exclusion criteria

* pregnancy * macroadenoma * neurologic signs due to tumor

Design outcomes

Primary

Measure	Time frame
serum prolactin level	2weeks and one month after treatment

Secondary

Measure	Time frame
change in LH,FSH and estradiol from baseline	one month ofter treatment

Countries

Iran

Contacts

Primary Contacthaleh rokni, proffessore assisstant

roknih@mums.ac.ir00981082976

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026